Company profile: Endologix
1.1 - Company Overview
Company description
- Provider of minimally invasive treatments for aortic disorders, offering the AFX2 Endovascular AAA System for abdominal aortic aneurysms with specific aneurysm morphology; the ALTO Abdominal Stent Graft System for infrarenal abdominal aortic aneurysms requiring specific vascular morphology; and the DETOUR System for percutaneous revascularization of symptomatic femoropopliteal lesions in patients suboptimal for surgical or alternative endovascular treatments.
Products and services
- ALTO Abdominal Stent Graft System: Endovascular, infrarenal-focused stent graft that treats abdominal aortic aneurysms requiring specific vascular morphology for repair, addressing anatomies suitable for endovascular AAA treatment
- DETOUR System: Percutaneous revascularization system for patients with symptomatic femoropopliteal lesions, intended for those considered suboptimal candidates for surgical or alternative endovascular treatments
- AFX2 Endovascular AAA System: Endovascular system treating abdominal aortic aneurysms, suitable for patients with specific aneurysm morphology, facilitating repair in anatomies with the specified morphology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Endologix
Silvergate Pharmaceuticals
HQ: United States
Website
- Description: Provider of pediatric medications, developing and commercializing innovative oral solutions that improve dosing accuracy, safety, and availability. Products include Xatmep (methotrexate) for pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis; Qbrelis (lisinopril) for hypertension (adults/pediatric 6+), adjunct heart failure, and acute MI in adults; and EPANED (enalapril) for hypertension (adults/pediatric >1 month), symptomatic heart failure, and asymptomatic left ventricular dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Silvergate Pharmaceuticals company profile →
ATS Medical
HQ: United States
Website
- Description: Provider of cardiovascular surgery medical devices, doing business as Medtronic ATS Medical, Inc.; manufactures, markets, and distributes mechanical heart valves (including the ATS Open Pivot Heart Valve), aortic valve graft prostheses, and other cardiovascular accessories.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ATS Medical company profile →
Kardium
HQ: Canada
Website
- Description: Provider of the Globe Pulsed Field System for the diagnosis and treatment of atrial fibrillation, integrating pulmonary vein isolation, high-definition mapping, and atrial ablation in a single catheter. Offers the Globe PF Mapping and Ablation System with a 122-electrode catheter, the Globe Catheter (30 mm spherical array, 122 electrodes), and the PULSAR clinical study evaluating safety and effectiveness.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kardium company profile →
NovaCardia
HQ: United States
Website
- Description: Provider of cardiovascular drug development and commercialization of novel small molecule drugs to improve care for patients with cardiovascular disease; a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NovaCardia company profile →
Amarin
HQ: Ireland
Website
- Description: Provider of prescription cardiovascular therapy and clinical research, including VASCEPA/VAZKEPA (icosapent ethyl) to reduce cardiovascular risk in patients with elevated triglycerides and established cardiovascular disease, and the REDUCE-IT global outcomes study evaluating VASCEPA in patients with controlled LDL-C and elevated triglycerides to reduce cardiovascular events.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amarin company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Endologix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Endologix
2.2 - Growth funds investing in similar companies to Endologix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Endologix
4.2 - Public trading comparable groups for Endologix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →